ArticleCureus2025
A Case Report of Pulmonary Tumor Thrombotic Microangiopathy Caused by Lung Adenocarcinoma: The Importance of Clinical Diagnosis and Monitoring Disease Progression.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pulmonary tumor thrombotic microangiopathy associated with prostate cancer achieving over 10-year survival: a case report.International cancer conference journal · 2026Article
- Pulmonary Tumor Thrombotic Microangiopathy in a Patient With Male Breast Cancer: A Report of a Rare Case.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare and fatal lung complication associated with cancer. Diagnosing PTTM is challenging due to its rapid progression and nonspecific clinical or imaging findings, which often result in postmortem identification. Treatment options are limited, and long-term management remains poorly understood. This report describes a 50-year-old patient with lung adenocarcinoma who was clinically diagnosed with PTTM and showed improvement with early chemotherapy initiation. Disease activity was controlled through multiple chemotherapy regimens, and recurrence was monitored using blood coagulation status and echocardiography. This case highlights the importance of early clinical diagnosis and ongoing monitoring of disease progression in PTTM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.